DESTINY-Breast03 Phase 3 Study Results

Primary Analysis from DS8201-A-U105: A 2-part, Open-label, Phase 1b Trial Assessing Trastuzumab Deruxtecan (T-DXd) with Nivolumab in Patients with HER2-expressing Advanced Breast Cancer Erika Hamilton, Charles L. Shapiro, Valentina Boni, Miguel Martin, Gianluca Del Conte, Javier Cortes, Laila Agrawal, Hendrik-Tobias Arkenau, Antoinette R. Tan, Philip Debruyne, Anna Minchom, Annemie Rutten, Frances Valdes-Albini, Evan Y. Yu, Fumitaka Suto, Fu-Chih Cheng, Bincy Augustine, Ben Cheng, Daniel Barrios, Sara A. Hurvitz Erika Hamilton, MD Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN, USA ESMO BC 2022 #1620 Oral Daiichi-Sankyo 60 00

View entire presentation